Effect of tezepelumab in patients with severe, uncontrolled asthma by age of onset, allergic status, and eosinophilic phenotype

被引：1

作者：

Mathur, S. K. ^{[1
]}

Hill, J. L. ^{[2
,3
]}

Ambrose, C. S. ^{[4
]}

Martin, N. ^{[5
,6
,8
,9
]}

Llanos, J-P ^{[7
]}

Martin, N. ^{[5
,6
,8
,9
]}

Colice, G. ^{[10
]}

机构：

[1] Univ Wisconsin, Dept Med, Div Allergy Pulm & Crit Care Med, Madison, WI USA

[2] San Tan Allergy & Asthma, Arizona Allergy & Immunol Res, Gilbert, AZ USA

[3] Arcadia Allergy & Asthma, Phoenix, AZ USA

[4] AstraZeneca, Resp & Immunol, BioPharmaceut Med, Gaithersburg, MD USA

[5] AstraZeneca, BioPharmaceut RandD, Resp & Immunol, Biometr,Late Stage Dev, Waltham, MA USA

[6] Cytel Inc, Waltham, MA USA

[7] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[8] AstraZeneca, Resp & Immunol, BioPharmaceut Med, Cambridge, England

[9] Univ Leicester, Leicester, Leics, England

[10] AstraZeneca, Late Stage Dev, Resp & Immunol, BioPharmaceut RandD, Gaithersburg, MD USA

来源：

关键词：

D O I：

10.1136/thorax-2023-BTSabstracts.125

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

S119

引用

页码：A86 / A86

页数：1